Literature DB >> 20138505

Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis.

Gaetan Des Guetz1, Patrick Nicolas, Gérard-Yves Perret, Jean-François Morere, Bernard Uzzan.   

Abstract

BACKGROUND: In stage III colorectal cancer (CRC), adjuvant chemotherapy (CT) is usually prescribed within two months after curative surgery. Whether or not delaying initiation of CT affects survival is still debated.
MATERIAL AND METHODS: We performed a meta-analysis (MA) of all published studies (full papers or abstracts) comparing delayed CT with standard care. Studies were obtained from a PubMed query (keywords: CRC, adjuvant treatment, delay of CT), a review (Chau et al., 2006), cross-checking references and abstracts from the proceedings of ASCO, ASCO GI and WCGI annual meetings. We chose a cutoff delay of 8 weeks. Risk Ratios (RRs) were calculated from the recorded events (deaths, relapses). We used EasyMA software (fixed-effect model).
RESULTS: Fourteen studies (including four abstracts) were identified (17,645 patients; 5,952 males, 5,151 females, mean age 70 years). Of these, three could not be statistically analysed and three used another cutoff (4, 5 or 6 weeks), leaving 8 studies for main MA (13,158 patients; 3,932 males, 3,644 females, 5,942 missing data; 5,576 colon cancers, 6,677 rectal, 1,265 missing data). Delaying CT more than 8 weeks was associated to worse Overall Survival (OS) (RR: 1.20; 95% Confidence Interval (CI) 1.15-1.26). In the MA including all studies whatever their cutoff, longer delay was similarly associated to a worse OS but not a worse Relapse-Free Survival (RFS) (five studies).
CONCLUSION: Adjuvant chemotherapy should be started within 8 weeks after surgery. Delaying the initiation of adjuvant CT for more than 8 weeks after surgery significantly decreased OS but not RFS. This discrepancy might be due to factors not directly related to cancer (post-operative complications, social status) or to a more accurate appraisal of death. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20138505     DOI: 10.1016/j.ejca.2010.01.020

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  74 in total

Review 1.  Adjuvant chemotherapy for rectal cancer: Is it needed?

Authors:  Kristijonas Milinis; Michael Thornton; Amir Montazeri; Paul S Rooney
Journal:  World J Clin Oncol       Date:  2015-12-10

Review 2.  Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma.

Authors:  Daneng Li; Eileen M O'Reilly
Journal:  Semin Oncol       Date:  2014-12-09       Impact factor: 4.929

3.  Impact on Loco-regional Control of Radiochemotherapeutic Sequence and Time to Initiation of Adjuvant Treatment in Stage II/III Rectal Cancer Patients Treated with Postoperative Concurrent Radiochemotherapy.

Authors:  Haeyoung Kim; Eui Kyu Chie; Yong Chan Ahn; Kyubo Kim; Won Park; Won Sup Yoon; Seung Jae Huh; Sung W Ha
Journal:  Cancer Res Treat       Date:  2014-04-22       Impact factor: 4.679

4.  Postoperative complications in patients with rectal cancer are associated with delays in chemotherapy that lead to worse disease-free and overall survival.

Authors:  Sarah E Tevis; Brittney M Kohlnhofer; Sarah Stringfield; Eugene F Foley; Bruce A Harms; Charles P Heise; Gregory D Kennedy
Journal:  Dis Colon Rectum       Date:  2013-12       Impact factor: 4.585

5.  Postoperative Complications Predict Long-term Outcome After Curative Resection for Perforated Colorectal Cancer.

Authors:  Shintaro Hashimoto; Kiyoaki Hamada; Yorihisa Sumida; Masato Araki; Kouki Wakata; Tota Kugiyama; Ayako Shibuya; Masato Nishimuta; Shigeyuki Morino; Masayuki Baba; Soichiro Kiya; Keisuke Ozeki; Akihiro Nakamura
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

6.  Colorectal Cancer Care Among Young Adult Patients After the Dependent Coverage Expansion Under the Affordable Care Act.

Authors:  Leticia Nogueira; Neetu Chawla; Xuesong Han; Ahmedin Jemal; K Robin Yabroff
Journal:  J Natl Cancer Inst       Date:  2020-10-01       Impact factor: 13.506

7.  Adequacy of the National Quality Forum's Colon Cancer Adjuvant Chemotherapy Quality Metric: Is 4 Months Soon Enough?

Authors:  Nader N Massarweh; Alex B Haynes; Yi-Ju Chiang; George J Chang; Y Nancy You; Barry W Feig; Janice N Cormier
Journal:  Ann Surg       Date:  2015-08       Impact factor: 12.969

8.  Implementation of an Enhanced Recovery Protocol Is Associated With On-Time Initiation of Adjuvant Chemotherapy in Colorectal Cancer.

Authors:  Taryn E Hassinger; J Hunter Mehaffey; Allison N Martin; Kristine Bauer-Nilsen; Florence E Turrentine; Robert H Thiele; Bethany M Sarosiek; Matthew J Reilley; Sook C Hoang; Charles M Friel; Traci L Hedrick
Journal:  Dis Colon Rectum       Date:  2019-11       Impact factor: 4.585

9.  Is pancreatic fistula associated with worse overall survival in patients with pancreatic carcinoma?

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Naru Kondo; Naoya Nakagawa; Hayato Sasaki; Taijiro Sueda
Journal:  World J Surg       Date:  2015-02       Impact factor: 3.352

10.  The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma.

Authors:  Wenchuan Wu; Jin He; John L Cameron; Martin Makary; Kevin Soares; Nita Ahuja; Neda Rezaee; Joseph Herman; Lei Zheng; Daniel Laheru; Michael A Choti; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang; Matthew J Weiss
Journal:  Ann Surg Oncol       Date:  2014-04-26       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.